CLINICAL TRIALS PROFILE FOR RELENZA
✉ Email this page to a colleague
All Clinical Trials for RELENZA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00784784 ↗ | Zanamivir Versus Trivalent Split Virus Influenza Vaccine | Completed | GlaxoSmithKline | Phase 3 | 2008-11-01 | This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers. |
| NCT00784784 ↗ | Zanamivir Versus Trivalent Split Virus Influenza Vaccine | Completed | Mount Sinai Hospital, Canada | Phase 3 | 2008-11-01 | This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers. |
| NCT00867139 ↗ | TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients | Completed | Fred Hutchinson Cancer Research Center | Phase 1/Phase 2 | 2009-03-01 | The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD |
| NCT00921726 ↗ | Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults | Completed | Johns Hopkins Bloomberg School of Public Health | Phase 1 | 2009-07-01 | Due in part to widespread availability of oseltamivir and clinical experience using oseltamivir to treat H5N1 influenza virus infections, many strains of influenza have become resistant to it. Other reliable methods of treating H5N1 must be identified in case of a pandemic. One such option is intravenous zanamivir used in combination with oseltamivir. The primary purpose of this study is to evaluate the interaction between oral oseltamivir and intravenous zanamivir administered as either a continuous or intermittent infusion in healthy adults. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RELENZA
Condition Name
Clinical Trial Locations for RELENZA
Trials by Country
Clinical Trial Progress for RELENZA
Clinical Trial Phase
Clinical Trial Sponsors for RELENZA
Sponsor Name
